Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Aberrant splicing in B-cell acute lymphoblastic leukemia.

Black KL, Naqvi AS, Asnani M, Hayer KE, Yang SY, Gillespie E, Bagashev A, Pillai V, Tasian SK, Gazzara MR, Carroll M, Taylor D, Lynch KW, Barash Y, Thomas-Tikhonenko A.

Nucleic Acids Res. 2019 Jan 25;47(2):1043. doi: 10.1093/nar/gky1231. No abstract available.

2.

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.

Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB, Felix CA.

Oncogene. 2018 Nov 26. doi: 10.1038/s41388-018-0567-7. [Epub ahead of print]

PMID:
30478448
3.

Aberrant splicing in B-cell acute lymphoblastic leukemia.

Black KL, Naqvi AS, Asnani M, Hayer KE, Yang SY, Gillespie E, Bagashev A, Pillai V, Tasian SK, Gazzara MR, Carroll M, Taylor D, Lynch KW, Barash Y, Thomas-Tikhonenko A.

Nucleic Acids Res. 2018 Nov 30;46(21):11357-11369. doi: 10.1093/nar/gky946.

4.

Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL.

Gagne AL, Maguire JA, Gandre-Babbe S, Chou ST, Tasian SK, Loh ML, Weiss MJ, Gadue P, French DL.

Stem Cell Res. 2018 Aug;31:157-160. doi: 10.1016/j.scr.2018.07.001. Epub 2018 Jul 5.

5.

Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?

Tasian SK.

Ther Adv Hematol. 2018 Jun;9(6):135-148. doi: 10.1177/2040620718774268. Epub 2018 May 17. Review.

6.

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.

Tasian SK, Casas JA, Posocco D, Gandre-Babbe S, Gagne AL, Liang G, Loh ML, Weiss MJ, French DL, Chou ST.

Leukemia. 2019 Jan;33(1):181-190. doi: 10.1038/s41375-018-0169-y. Epub 2018 Jun 8.

7.

Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.

Ding YY, Stern JW, Jubelirer TF, Wertheim GB, Lin F, Chang F, Gu Z, Mullighan CG, Li Y, Harvey RC, Chen IM, Willman CL, Hunger SP, Li MM, Tasian SK.

Haematologica. 2018 Sep;103(9):e427-e431. doi: 10.3324/haematol.2018.192088. Epub 2018 May 17. No abstract available.

8.

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.

Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M.

Oncotarget. 2018 Jan 17;9(8):8027-8041. doi: 10.18632/oncotarget.24261. eCollection 2018 Jan 30.

9.

Targeting Leukemia Stem Cells in the Bone Marrow Niche.

Tasian SK, Bornhäuser M, Rutella S.

Biomedicines. 2018 Feb 21;6(1). pii: E22. doi: 10.3390/biomedicines6010022. Review.

10.

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

Gotesman M, Vo TT, Herzog LO, Tea T, Mallya S, Tasian SK, Konopleva M, Fruman DA.

Oncotarget. 2018 Jan 6;9(5):6562-6571. doi: 10.18632/oncotarget.24020. eCollection 2018 Jan 19.

11.

Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.

Sexauer AN, Tasian SK.

Front Pediatr. 2017 Nov 20;5:248. doi: 10.3389/fped.2017.00248. eCollection 2017. Review.

12.

How is the Ph-like signature being incorporated into ALL therapy?

Maese L, Tasian SK, Raetz EA.

Best Pract Res Clin Haematol. 2017 Sep;30(3):222-228. doi: 10.1016/j.beha.2017.06.001. Epub 2017 Jun 15. Review.

13.

Philadelphia chromosome-like acute lymphoblastic leukemia.

Tasian SK, Loh ML, Hunger SP.

Blood. 2017 Nov 9;130(19):2064-2072. doi: 10.1182/blood-2017-06-743252. Epub 2017 Oct 2. Review.

14.

Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.

Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, Weissman JS, Loh ML, Müschen M, Tasian SK, Bassik MC, Kampmann M, Pufall MA.

Blood. 2017 Jun 1;129(22):3000-3008. doi: 10.1182/blood-2017-02-766204. Epub 2017 Apr 19.

15.

A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).

Rheingold SR, Tasian SK, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Minard CG, Fox E, Weigel BJ, Blaney SM.

Br J Haematol. 2017 May;177(3):467-474. doi: 10.1111/bjh.14569. Epub 2017 Mar 14.

16.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.

17.

Improved surfaceome coverage with a label-free nonaffinity-purified workflow.

Glisovic-Aplenc T, Gill S, Spruce LA, Smith IR, Fazelinia H, Shestova O, Ding H, Tasian SK, Aplenc R, Seeholzer SH.

Proteomics. 2017 Apr;17(7). doi: 10.1002/pmic.201600344. Epub 2017 Mar 6.

18.

Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.

Tasian SK, Hunger SP.

Br J Haematol. 2017 Mar;176(6):867-882. doi: 10.1111/bjh.14474. Epub 2016 Dec 16. Review.

19.

High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL.

Tasian SK, Hurtz C, Wertheim GB, Bailey NG, Lim MS, Harvey RC, Chen IM, Willman CL, Astles R, Zebrowski A, Reshmi SC, Li MM, Frey NV, Luger SM, Carroll M, Perl AE.

Leukemia. 2017 Apr;31(4):981-984. doi: 10.1038/leu.2016.375. Epub 2016 Dec 9. No abstract available.

20.

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Tasian SK, Teachey DT, Li Y, Shen F, Harvey RC, Chen IM, Ryan T, Vincent TL, Willman CL, Perl AE, Hunger SP, Loh ML, Carroll M, Grupp SA.

Blood. 2017 Jan 12;129(2):177-187. doi: 10.1182/blood-2016-05-707653. Epub 2016 Oct 24.

21.

Mixed Phenotype Acute Leukemia with Low Hypodiploidy in a Pediatric Patient.

Salazar EG, Wertheim GB, Biegel JA, Hwang W, Tasian SK, Rheingold SR.

J Pediatr Oncol. 2015;3(1):24-28. Epub 2015 Mar 25.

22.
23.

Childhood acute lymphoblastic leukemia: Integrating genomics into therapy.

Tasian SK, Loh ML, Hunger SP.

Cancer. 2015 Oct 15;121(20):3577-90. doi: 10.1002/cncr.29573. Epub 2015 Jul 20. Review.

24.

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PH, Grupp SA, Fry TJ.

Blood. 2015 Jul 30;126(5):629-39. doi: 10.1182/blood-2014-11-612903. Epub 2015 Jun 3.

25.

Histology of Testicular Biopsies Obtained for Experimental Fertility Preservation Protocol in Boys with Cancer.

Pietzak EJ 3rd, Tasian GE, Tasian SK, Brinster RL, Carlson C, Ginsberg JP, Kolon TF.

J Urol. 2015 Nov;194(5):1420-4. doi: 10.1016/j.juro.2015.04.117. Epub 2015 May 30.

26.

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).

Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM.

Pediatr Blood Cancer. 2015 Oct;62(10):1717-24. doi: 10.1002/pbc.25575. Epub 2015 May 13.

27.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT.

Blood. 2015 Mar 12;125(11):1759-67. doi: 10.1182/blood-2014-06-580480. Epub 2015 Feb 2.

28.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG.

N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088.

29.

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.

Tasian SK, Teachey DT, Rheingold SR.

Front Oncol. 2014 May 16;4:108. doi: 10.3389/fonc.2014.00108. eCollection 2014. Review.

30.

Molecular therapeutic approaches for pediatric acute myeloid leukemia.

Tasian SK, Pollard JA, Aplenc R.

Front Oncol. 2014 Mar 18;4:55. doi: 10.3389/fonc.2014.00055. eCollection 2014. Review.

31.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.

Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4. Erratum in: Blood. 2016 Nov 24;128(21):2585.

32.

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.

Gandre-Babbe S, Paluru P, Aribeana C, Chou ST, Bresolin S, Lu L, Sullivan SK, Tasian SK, Weng J, Favre H, Choi JK, French DL, Loh ML, Weiss MJ.

Blood. 2013 Jun 13;121(24):4925-9. doi: 10.1182/blood-2013-01-478412. Epub 2013 Apr 25.

33.

Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.

Kavcic M, Fisher BT, Li Y, Seif AE, Torp K, Walker DM, Huang YS, Lee GE, Tasian SK, Vujkovic M, Bagatell R, Aplenc R.

Cancer. 2013 May 15;119(10):1916-23. doi: 10.1002/cncr.27957. Epub 2013 Feb 21.

34.

Labial ecthyma gangrenosum in an immunocompromised infant with leukemia: heightening awareness for the urologist.

Pulido J, McMahon P, Treat JR, Gunselman J, Tasian GE, Tasian SK.

Urology. 2012 Dec;80(6):1366-8. doi: 10.1016/j.urology.2012.08.020. Epub 2012 Oct 2.

35.

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG, Seif AE, Barrett DM, Chen IM, Collins JR, Mullighan CG, Hunger SP, Harvey RC, Willman CL, Fridman JS, Loh ML, Grupp SA, Teachey DT.

Blood. 2012 Oct 25;120(17):3510-8. doi: 10.1182/blood-2012-03-415448. Epub 2012 Sep 6.

36.

Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.

Tasian SK, Doral MY, Borowitz MJ, Wood BL, Chen IM, Harvey RC, Gastier-Foster JM, Willman CL, Hunger SP, Mullighan CG, Loh ML.

Blood. 2012 Jul 26;120(4):833-42. doi: 10.1182/blood-2011-12-389932. Epub 2012 Jun 8.

37.

Development of anaplastic Wilms tumor and subsequent relapse in a child with diaphanospondylodysostosis.

Tasian SK, Kim GE, Miniati DN, DuBois SG.

J Pediatr Hematol Oncol. 2012 Oct;34(7):548-51.

38.

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.

Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, Camitta BM, Carroll AJ, Devidas M, Pullen DJ, Payne-Turner D, Tasian SK, Reshmi S, Cottrell CE, Reaman GH, Bowman WP, Carroll WL, Loh ML, Winick NJ, Hunger SP, Willman CL.

Blood. 2012 Apr 12;119(15):3512-22. doi: 10.1182/blood-2011-11-394221. Epub 2012 Feb 24.

39.

Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.

Tasian SK, Loh ML.

Crit Rev Oncog. 2011;16(1-2):13-24. Review.

40.

JAK mutations in high-risk childhood acute lymphoblastic leukemia.

Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8. doi: 10.1073/pnas.0811761106. Epub 2009 May 22.

41.

Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches.

Fry TJ, Shand JL, Milliron M, Tasian SK, Mackall CL.

Cancer Immunol Immunother. 2009 Aug;58(8):1257-64. doi: 10.1007/s00262-008-0638-7. Epub 2009 Jan 13.

42.

Influenza-associated morbidity in children with cancer.

Tasian SK, Park JR, Martin ET, Englund JA.

Pediatr Blood Cancer. 2008 May;50(5):983-7. doi: 10.1002/pbc.21472.

Supplemental Content

Loading ...
Support Center